Live | Norge | Sverige | Danmark | Europa | USA | Valuta | Råvarer | Gråmarked | Fond | NDXForsinkede kurser. Sist oppdatert: torsdag 19. juli
Største handler

14/09-2017 13:15:00: (ALK-B.CPH, E-ALKBC.BTSE) Successful Phase III trial for ALK.s tree allergy SLIT-tablet

focusing on allergy 
prevention, diagnosis and treatment. ALK is a world leader in allergy 
immunotherapy . a treatment of the underlying cause of allergy. The company has 
approximately 2,300 employees, with subsidiaries, production facilities and 
distributors worldwide. ALK has entered into partnership agreements with Torii, 
Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets 
in Japan, Russia, and South-East Asia, and Australia and New Zealand, 
respectively. The company is headquartered in Hørsholm, Denmark, and listed on 
Nasdaq Copenhagen. Find more information at believed to have symptoms that are not well controlled by 
conventional symptom-relieving medications. For some of these people with 
uncontrolled allergies to tree pollen, ALK.s tablet may become a relevant 
treatment option.  
ALK expects to submit a European and possibly also a Canadian registration 
application for the tree SLIT-tablet in 2018.  
                                 ALK-Abelló A/S 
For further information please contact: 
Henrik Jacobi, Executive Vice President, Research and Development, tel. +45 
4574 7576  
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 
Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014 
About ALK 
ALK is a research-driven global pharmaceutical company controlled, double-blind, multi-centre trial 
involving 634 patients aged 12-65 years in eight European countries. A 
preceding Phase II trial in an environmental exposure chamber showed that the 
tablet significantly reduced patients. symptoms in response to both birch and 
oak pollen compared with placebo.  
Allergic rhinitis (with or without conjunctivitis) represents a global health 
problem affecting 10 to 25% of the population. The prevalence in the general 
population in Europe and North America is ~20%. In Northern and Central Europe, 
USA and Canada, respiratory allergies are commonly caused by allergens from the 
birch homologous group of trees, which also includes alder, beech, hazel and 
oak. ALK estimates that around 15 million Europeans have tree allergies of 
which ~10% ical effect seen in this trial was among the most significant that we have 
ever seen in field studies of allergy immunotherapy, which means that we have 
developed a unique compound..  
He continues: .With SLIT-tablets for house dust mite, grass, ragweed and 
Japanese cedar allergies already filed or marketed, these trial results 
represent an important step forward for ALK in completing its tablet portfolio. 
With these five tablets, we will be able to effectively cover more than 80% of 
global respiratory allergies."  
ALK initiated the Phase III clinical trial in 2016 to evaluate the efficacy and 
safety of the tree SLIT-tablet compared with placebo in adult and adolescent 
patients with birch pollen allergic rhinitis and/or conjunctivitis. The trial 
was a randomised, placebo-relieving 
medication, measured during the birch pollen season. Treatment with the tree 
SLIT-tablet reduced the total combined score (primary endpoint) by 39.6% 
compared to placebo. The results were highly statistically significant (p < 
0.0001). The efficacy was similar when analysing data for the entire tree 
pollen season (i.e. including the alder and hazel pollen seasons). The trial 
also showed that the treatment was well-tolerated by patients, with no new or 
unexpected adverse events reported compared to previous clinical trials with 
Henrik Jacobi, ALK.s Executive Vice President, Research and Development, says: 
"We are extremely pleased to see such a clear and clinically meaningful 
treatment effect of the tree allergy immunotherapy tablet. In fact, the 
Inside information

Successful Phase III trial for ALK.s tree allergy SLIT-tablet

Copenhagen, 2017-09-14 13:15 CEST (GLOBE NEWSWIRE) --  
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced the successful 
outcome of a pivotal Phase III clinical trial of its tree allergy sublingual 
immunotherapy (SLIT) tablet, with the trial meeting its primary efficacy 
endpoint. The tree SLIT-tablet is important to ALK's efforts to develop a full 
tablet portfolio for people suffering from the most common respiratory 
allergies. ALK is currently the only company that has completed Phase III 
clinical development with a tree SLIT-tablet.  
The primary endpoint of the trial was the daily total combined score, which is 
the sum of the allergic symptom score and the use of symptom-

Ekstern link:
Ekstern link:

Nyheten er levert av OMX.

Utforming |  Hjelp |  Utskrift  | Bytt til sanntid Ingen åpne markeder
torsdag 19/07-2018 00:27:29